Please ensure Javascript is enabled for purposes of website accessibility

Walgreen's Sunny Sales

By Steven Mallas – Updated Nov 16, 2016 at 5:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Walgreen has a resplendently ruddy June, with comp sales increasing more than 10%.

I must confess up front to an addiction. It doesn't involve drugs or alcohol, thankfully. It has to do with same-store sales. When it comes to this number, I am hopeless, always in need of a double-digit increase for a fix. Well, I found one in Walgreen (NYSE:WAG).

The retail pharmacy reported a 15.6% increase in overall sales when compared with June 2003, coming in at $3.126 billion versus $2.704 billion. That's a wonderful figure in and of itself, but the comp-sales component of that total represented a 10.6% increase, and we all know that comp sales are where it's at because these revenues, derived from stores that have been open for a year or longer, tend to more accurately reflect the underlying health of a retail chain. Stores that have just opened or haven't been around as long as a year tend to skew the interpretation of fundamental growth trends, on the theory that people might be transiently drawn to a new location; the best measure of loyalty and success comes from sales data at aging locations.

So I love this metric, and I love these results. Walgreen had a more mellow outing in May with same-store sales, which came in at 8.5%. But since the company's last quarterly checkup was quite copacetic, I can dismiss those results (besides, anything more than 8% is still dandy).

Walgreen will have to watch out going forward, since CVS (NYSE:CVS) will be closing soon on its deal to buy more than 1,200 Eckerd drugstore locations from J.C. Penney (NYSE:JCP), with the rest going to Canadian concern Jean Coutu, which operates the Brooks Pharmacy stores.

Rite Aid (NYSE:RAD) will also need to be wary of this event, as I mentioned in my recent piece on its latest earnings. I received an avalanche of correspondence -- well, maybe not an avalanche, but more than usual -- about that article; many readers took me to task for not recognizing the potential in Rite Aid stock. Let me say again that if one is a long-term investor, I see more safety in either CVS or Walgreen; I do, however, recognize the improving environment Rite Aid has engineered for itself. To me, CVS and Walgreen are like the Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) of this sector, and I just feel more comfortable with those two companies. I do, however, wish all Rite Aid stakeholders the best of luck, and I definitely see the possibility of positive catalysts on the horizon for the chain, which would lead to share appreciation. Nevertheless, I still feel it is a speculative bet at this juncture.

Well, the shakes have ceased since I got my fix for double-digit-comp-sales increases (I didn't think I was going to make it). In closing, why not check out this chart of all three drugstore companies mentioned and see how things have been faring. CVS is certainly looking like the healthy horse.

Fool contributor Steven Mallas owns shares of Coca-Cola, but none of the other companies mentioned.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Coca-Cola Company Stock Quote
The Coca-Cola Company
KO
$58.60 (-1.11%) $0.66
Pepsico, Inc. Stock Quote
Pepsico, Inc.
PEP
$168.52 (-0.05%) $0.08
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$98.35 (-1.48%) $-1.48
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.83 (-1.47%) $0.49
J. C. Penney Company, Inc. Stock Quote
J. C. Penney Company, Inc.
JCPN.Q
Rite Aid Corporation Stock Quote
Rite Aid Corporation
RAD
$7.01 (-0.99%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.